Valentin, GGHernandez-Boluda, JCOsorio, SCorrea, JGSanchez-Guijo, FGómez-Casares, MTDurán, SPortero, MABoqué, CPérez-Encinas, MMata, MIRomo, MAVallansot, RPayer, ANoya, MSCaballero, GRamirez Sánchez, MJJimenez-Velasco, ASteegmann, JL2016-10-032016-10-032016-06Valentin GG, Hernandez-Boluda JC, Osorio S, Correa JG, Sanchez-Guijo F, Gómez-Casares MT, et al.Safety and efficacy of ponatinib in real world clinical practice. Results from the Spanish Compassionate Use Program. A GELMC study. Haematologica. 2016; 101 (s1) PB18320390-6078http://hdl.handle.net/10668/2441Aims: The purpose of this study is to provide safety and efficacy information from patients treated with ponatinib in real world clinical practice.enHumanosImidazolesLeucemia mielogenosa crónica BCR-ABL positivaPiridacinasRiesgoMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::ImidazolesMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::PyridazinesMedical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Probability::Riskconference presentationopen access1592-8721